Insider Trading Alert - RSG, HAL And AVNR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 17, 2014, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $336,996,000.00.

Highlighted Stocks Traded by Insiders:

Republic Services (RSG) - FREE Research Report

Cascade Investment Llc, who is 10% Owner at Republic Services, bought 161,300 shares at $39.11 on Sept. 17, 2014. Following this transaction, the 10% Owner owned 102.9 million shares meaning that the stake was boosted by 0.16% with the 161,300-share transaction.

The shares most recently traded at $39.25, up $0.14, or 0.34% since the insider transaction. Historical insider transactions for Republic Services go as follows:

  • 4-Week # shares bought: 2.2 million
  • 12-Week # shares bought: 9.9 million
  • 24-Week # shares bought: 13.1 million

The average volume for Republic Services has been 1.6 million shares per day over the past 30 days. Republic Services has a market cap of $13.9 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 18.83% year-to-date as of the close of trading on Tuesday.

Republic Services, Inc., together with its subsidiaries, provides non-hazardous solid waste collection, transfer, and recycling and disposal services for commercial, industrial, municipal, and residential customers in the United States and Puerto Rico. The stock currently has a dividend yield of 2.86%. The company has a P/E ratio of 19.7. Currently, there are 4 analysts who rate Republic Services a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RSG - FREE

TheStreet Quant Ratings rates Republic Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Republic Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Halliburton (HAL) - FREE Research Report

Pope Lawrence J, who is EVP Administration & CHRO at Halliburton, sold 3,000 shares at $65.57 on Sept. 17, 2014. Following this transaction, the EVP Administration & CHRO owned 147,126 shares meaning that the stake was reduced by 2% with the 3,000-share transaction.

The shares most recently traded at $66.24, up $0.67, or 1.01% since the insider transaction. Historical insider transactions for Halliburton go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 39,001
  • 24-Week # shares sold: 107,489

The average volume for Halliburton has been 6.8 million shares per day over the past 30 days. Halliburton has a market cap of $56.4 billion and is part of the basic materials sector and energy industry. Shares are up 32.59% year-to-date as of the close of trading on Tuesday.

Halliburton Company provides a range of services and products for the exploration, development, and production of oil and natural gas to oil and gas companies worldwide. The company operates in two segments, Completion and Production, and Drilling and Evaluation. The stock currently has a dividend yield of 0.91%. The company has a P/E ratio of 20.1. Currently, there are 18 analysts who rate Halliburton a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HAL - FREE

TheStreet Quant Ratings rates Halliburton as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Halliburton Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AVANIR Pharmaceuticals (AVNR) - FREE Research Report

Ocampo Christine, who is Vice President, Finance at AVANIR Pharmaceuticals, sold 55,000 shares at $9.45 on Sept. 17, 2014. Following this transaction, the Vice President, Finance owned 79,871 shares meaning that the stake was reduced by 40.78% with the 55,000-share transaction.

Palekar Rohan, who is SVP & Chief Commercial Officer at AVANIR Pharmaceuticals, sold 25,000 shares at $11.50 on Sept. 17, 2014. Following this transaction, the SVP & Chief Commercial Officer owned 266,750 shares meaning that the stake was reduced by 8.57% with the 25,000-share transaction.

The shares most recently traded at $12.49, up $0.99, or 7.93% since the insider transaction. Historical insider transactions for AVANIR Pharmaceuticals go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,110
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 11,780
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 493,135

The average volume for AVANIR Pharmaceuticals has been 3.5 million shares per day over the past 30 days. AVANIR Pharmaceuticals has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 258.93% year-to-date as of the close of trading on Tuesday.

Avanir Pharmaceuticals, Inc., together with its subsidiaries, is engaged in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. Currently, there are 3 analysts who rate AVANIR Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AVNR - FREE

TheStreet Quant Ratings rates AVANIR Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and deteriorating net income. Get the full AVANIR Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Mixed, Dollar Firm as Trade Tensions Keep Investors Cautious

Global Stocks Mixed, Dollar Firm as Trade Tensions Keep Investors Cautious

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries